Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00261404 · ClinicalTrials.gov registry record · Phase 2
TNFerade™ Biologic Plus Radiation for Metastatic Melanoma
A Phase 2 study of Melanoma, sponsored by GenVec.
- Completed
- Registry status
- Phase 2
- Development phase
- 1
- Study location
NCT00261404: Completed Phase 2 study of Melanoma, sponsored by GenVec.
NCT00261404 is a Phase 2 study of Melanoma that has completed, run by GenVec. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00261404, a Phase 2 study of Melanoma, has completed, sponsored by GenVec.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1
- Study location
Study Summary
Phase II, open label study in which patients with metastatic melanoma (stage III or IV) who have cancer which is not considered curable by surgery will receive intratumoral injections of TNFerade™ plus radiation as a 4-week treatment, followed by a 3 year follow-up period.
Conditions Studied
Interventions
- DRUG TNFerade™
Study Locations (1)
Texas
- Mary Crowley Medical Research Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 2 |
What the finished NCT00261404 record still lists
NCT00261404 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 1 condition, with Melanoma appearing as the primary indexed condition, and to 1 intervention - of which TNFerade™ is the first listed.
NCT00261404 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT00261404 about?
NCT00261404 is a clinical study titled "TNFerade™ Biologic Plus Radiation for Metastatic Melanoma". Phase II, open label study in which patients with metastatic melanoma (stage III or IV) who have cancer which is not considered curable by surgery will receive intratumoral injections of TNFerade™ plus radiation as a 4-week treatment, followed by a 3 year follow-up period.
What is the current status of trial NCT00261404?
This trial is currently completed. It is a Phase 2 study.
What conditions does trial NCT00261404 study?
This clinical trial studies the following conditions: Melanoma.
What interventions are being tested in trial NCT00261404?
The interventions under investigation include: TNFerade™ (DRUG).
Who is sponsoring clinical trial NCT00261404?
This trial is sponsored by GenVec, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00261404 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED
RECRUITING · Phase 2
-
Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma
RECRUITING · Phase 2
-
A Study of IBI363 in Subjects with Advanced Solid Malignancies
RECRUITING · Phase 2
-
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
RECRUITING · Phase 2
-
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
RECRUITING · Phase 2